Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial

被引:26
|
作者
Chakrabarti, D. [1 ]
Rajan, S. [2 ]
Akhtar, N. [2 ]
Qayoom, S. [3 ]
Gupta, S. [2 ]
Verma, M. [1 ]
Srivastava, K. [1 ]
Kumar, V [2 ]
Bhatt, M. L. B. [1 ]
Gupta, R. [1 ]
机构
[1] King Georges Med Univ, Dept Radiat Oncol, Lucknow 226003, Uttar Pradesh, India
[2] King Georges Med Univ, Dept Surg Oncol, Lucknow, Uttar Pradesh, India
[3] King Georges Med Univ, Dept Pathol, Lucknow, Uttar Pradesh, India
关键词
TOTAL MESORECTAL EXCISION; ADJUVANT CHEMOTHERAPY; PREOPERATIVE RADIOTHERAPY; STOCKHOLM III; NEOADJUVANT CHEMORADIATION; TUMOR-REGRESSION; DELAYED SURGERY; SURVIVAL; THERAPY; OXALIPLATIN;
D O I
10.1093/bjs/znab020
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The trial hypothesis was that, in a resource-constrained situation, short-course radiotherapy would improve treatment compliance compared with conventional chemoradiotherapy for locally advanced rectal cancer, without compromising oncological outcomes. Methods: In this open-label RCT, patients with cT3, cT4 or node-positive non-metastatic rectal cancer were allocated randomly to 5 x 5 Gy radiotherapy and two cycles of XELOX (arm A) or chemoradiotherapy with concurrent capecitabine (arm B), followed by total mesorectal excision in both arms. All patients received a further six cycles of adjuvant chemotherapy with the XELOX regimen. The primary endpoint was treatment compliance, defined as the ability to complete planned treatment, including neoadjuvant radiochemotherapy, surgery, and adjuvant chemotherapy to a dose of six cycles. Results: Of 162 allocated patients, 140 were eligible for analysis: 69 in arm A and 71 in arm B. Compliance with planned treatment (primary endpoint) was greater in arm A (63 versus 41 per cent; P = 0.005). The incidence of acute toxicities of neoadjuvant therapy was similar (haematological: 28 versus 32 per cent, P = 0.533; gastrointestinal: 14 versus 21 per cent, P = 0.305; grade 2 versus 4 per cent, P = 1.000). Delays in radiotherapy were less common in arm A (9 versus 45 per cent; P < 0.001), and overall times for completion of neoadjuvant treatment were shorter (P < 0.001). The rates of RO resection (87 versus 90 per cent; P = 0.554), sphincter preservation (32 versus 35 per cent; P = 0.708), pathological complete response (12 versus 10 per cent; P = 0.740), and overall tumour downstaging (75 versus 75 per cent; P = 0.920) were similar. Downstaging of the primary tumour (ypT) was more common in arm A (P = 0.044). There was no difference in postoperative complications between trial arms (P = 0.838). Conclusion: Reduced treatment delays and a higher rate of compliance were observed with treatment for short-course radiotherapy with consolidation chemotherapy, with no difference in early oncological surgical outcomes. In time- and resource-constrained rectal cancer units in developing countries, short-course radiotherapy should be the standard of care.
引用
收藏
页码:511 / 520
页数:10
相关论文
共 50 条
  • [21] Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial
    Kim, Min Jung
    Lee, Dae Won
    Kang, Hyun-Cheol
    Park, Ji Won
    Ryoo, Seung-Bum
    Han, Sae-Won
    Kim, Kyung Su
    Chie, Eui Kyu
    Oh, Jae Hwan
    Jeong, Woon Kyung
    Kim, Byoung Hyuck
    Nam, Eun Mi
    Jeong, Seung-Yong
    BMC CANCER, 2023, 23 (01)
  • [22] Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial
    Min Jung Kim
    Dae Won Lee
    Hyun-Cheol Kang
    Ji Won Park
    Seung-Bum Ryoo
    Sae-Won Han
    Kyung Su Kim
    Eui Kyu Chie
    Jae Hwan Oh
    Woon Kyung Jeong
    Byoung Hyuck Kim
    Eun Mi Nam
    Seung-Yong Jeong
    BMC Cancer, 23 (1)
  • [23] Comparison of Overall Response to Neoadjuvant Short Course Radiotherapy Followed by Consolidation Chemotherapy with Long Course Chemoradiotherapy in Locally Advanced Rectal Cancer
    Amariyil, A.
    Pathy, S.
    Sharma, A.
    Kumar, S.
    Pramanik, R.
    Dash, N. Ranjan
    Bhoriwal, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E155 - E156
  • [24] Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer
    Minsky, Bruce D.
    Roedel, Claus
    Valentini, Vincenzo
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (10): : 1223 - 1231
  • [25] Short-Course Radiotherapy in Locally Advanced Rectal Cancer
    Cambray, Maria
    Gonzalez-Viguera, Javier
    Angel Berenguer, Miguel
    Macia, Miquel
    Losa, Ferran
    Soler, Gemma
    Frago, Ricard
    Castellvi, J.
    Guino, E.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2020, 11
  • [26] Short-course versus long-course neoadjuvant radiotherapy for lower rectal cancer: a systematic review
    Sajid, M. S.
    Siddiqui, M. R. S.
    Kianifard, B.
    Baig, M. K.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2010, 179 (02) : 165 - 171
  • [27] Short-course versus long-course neoadjuvant radiotherapy for lower rectal cancer: a systematic review
    M. S. Sajid
    M. R. S. Siddiqui
    B. Kianifard
    M. K. Baig
    Irish Journal of Medical Science, 2010, 179 : 165 - 171
  • [28] Induction short-course radiotherapy with consolidation chemotherapy for locally-advanced rectal cancer: Is a long run and short slide preferred?
    Stewart, David B.
    SURGERY OPEN SCIENCE, 2024, 18 : 28 - 28
  • [29] Unconsolidated Results of Consolidation Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer Reply
    Tang, Yuan
    Zhou, Hai-Tao
    Li, Ye-Xiong
    Jin, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 4029 - +
  • [30] Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy
    Bercz, A.
    Park, B. K.
    Pappou, E.
    Nemirovsky, D.
    Sarkar, R.
    Yamner, M.
    Omer, D.
    Verheij, F. S.
    Alvarez, J.
    Atri, P.
    Reyngold, M.
    Yaeger, R.
    Wei, I. H.
    Wu, A.
    Raj, N.
    Widmar, M.
    Hajj, C.
    Kim, M. J.
    Rao, D.
    Nash, G. M.
    Williams, V.
    Shia, J.
    Segal, N. H.
    Diaz, L.
    Ganesh, K.
    Weiser, M. R.
    Gollub, M. J.
    Paty, P. B.
    Horvat, N.
    Zinovoy, M.
    O'Brien, D. Roth
    Sanchez-Vega, F.
    Saltz, L. B.
    Crane, C. H.
    Cercek, A.
    Gonen, M.
    Garcia-Aguilar, J.
    Smith, J. J.
    Romesser, P. B.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1003 - 1014